TUM Venture Labs, BioLabs and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups by providing access to state-of-the-art lab infrastructure, expert mentoring, and global industry networks.
Located in a refurbished 1,800-square-meter facility, BioLabs|TUM will offer fully equipped laboratories and office space for 15–20 start-ups. The hub is designed to accelerate the development of breakthrough therapies by connecting scientific talent with venture capital and pharmaceutical expertise.
“We are thrilled to announce this collaboration with TUM Venture Labs and Lilly to launch BioLabs|TUM in Munich – marking a major milestone in expanding our innovation ecosystem in Germany,” said Johannes Fruehauf, MD, PhD, Founder & CEO of BioLabs. “With world-class science, top academic institutions, and rising investor interest, Munich is the ideal launchpad for the next generation of biotech entrepreneurs.”
The collaboration brings together BioLabs’ proven coworking lab model, TUM Venture Labs’ academic innovation engine, and Lilly’s global R&D and venture capital reach. Start-ups selected for the program will benefit from tailored programming, strategic guidance, and access to Lilly’s scientific experts.
